| Literature DB >> 28980624 |
Orla Hardiman1, Ammar Al-Chalabi2, Adriano Chio3, Emma M Corr1, Giancarlo Logroscino4, Wim Robberecht5, Pamela J Shaw6, Zachary Simmons7, Leonard H van den Berg8.
Abstract
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria.Entities:
Mesh:
Year: 2017 PMID: 28980624 DOI: 10.1038/nrdp.2017.71
Source DB: PubMed Journal: Nat Rev Dis Primers ISSN: 2056-676X Impact factor: 52.329